Desmoplastic Melanoma

What Is Desmoplastic Melanoma

Desmoplastic melanoma is a rare variant of cutaneous melanoma characterized by a prominent fibrous, scar‑like stroma that surrounds malignant melanocytes. The term “desmoplastic” refers to the dense collagenous reaction that makes the tumor feel firm and often mimics a benign scar. It accounts for approximately 1 to 4 percent of all invasive melanomas and most frequently arises on chronically sun‑damaged skin of the head and neck in adults over the age of 60. Because the lesion can be subtle, diagnosis is often delayed, which influences management decisions.

Definition and Epidemiology

The neoplasm is defined by the World Health Organization as a melanoma with a predominant desmoplastic component comprising more than 90 percent of the tumor volume in the pure form. Incidence rates rise with cumulative ultraviolet exposure, and men are affected slightly more often than women. The median age at presentation is in the early seventies, and the scalp, face, and neck together represent the majority of primary sites. Rarely, desmoplastic melanoma develops on mucosal surfaces or in areas without obvious sun damage.

Risk Factors

Chronic ultraviolet radiation, especially ultraviolet‑A, is the principal environmental risk factor, and the disease is strongly associated with actinic keratosis and lentigo maligna in the same field. Immunosuppression, either iatrogenic or due to disease, modestly increases risk. A personal or family history of melanoma, fair skin phenotype (Fitzpatrick I‑II), and previous radiation therapy to the head and neck are additional contributors. Occupational outdoor exposure and use of photosensitizing medications may also play a role.

Pure Versus Mixed Desmoplastic Melanoma

Pathologists separate desmoplastic melanoma into pure and mixed categories based on the proportion of desmoplastic stroma. Pure desmoplastic melanoma shows a desmoplastic component exceeding 90 percent, while mixed desmoplastic melanoma contains a significant conventional melanoma component, usually 10 to 50 percent, alongside the fibrous areas. This distinction matters because pure tumors tend to have a lower rate of sentinel lymph node metastasis but a higher propensity for local recurrence and perineural invasion. Mixed tumors behave more like conventional melanoma with respect to nodal spread.

Clinical Appearance

Typical Lesion Characteristics

Clinically, desmoplastic melanoma often presents as a flesh‑colored, pink, or slightly erythematous plaque or nodule that feels firm or indurated on palpation. The surface may be smooth, slightly scaly, or ulcerated, and the lesion can slowly enlarge over months to years. Because the tumor lacks the typical dark pigmentation of conventional melanoma, patients and clinicians may mistake it for a benign scar, dermatofibroma, basal cell carcinoma, or a non‑healing wound. The absence of the classic ABCDE criteria (asymmetry, border irregularity, color variation, diameter >6 mm, evolution) contributes to diagnostic delay.

Dermoscopic Features

Dermoscopy of desmoplastic melanoma typically reveals a structureless, pink‑white background with fine linear vessels, shiny white streaks (chrysalis structures), and occasional peripheral pigment network remnants. The absence of a typical pigmented network and the presence of polymorphous vessels help differentiate it from basal cell carcinoma and scar tissue. However, dermoscopic sensitivity is limited, and a high index of suspicion remains essential for lesions on sun‑damaged skin of older adults.

Mimics and Differential Diagnosis

• Scar or keloid – firm, skin‑colored, history of trauma or surgery
• Dermatofibroma – dimple sign, usually on extremities
• Basal cell carcinoma – pearly telangiectatic surface, rolled borders
• Squamous cell carcinoma – keratotic, often on sun‑exposed skin
• Desmoplastic nevus – benign, usually smaller, lacks atypia

Nerve Involvement (Neurotropism)

Neurotropism, also called perineural invasion, describes the tendency of desmoplastic melanoma cells to grow along and within nerve sheaths. This feature is identified microscopically when tumor cells are seen tracking alongside or infiltrating nerves. Clinically, neurotropism may manifest as localized pain, paresthesia, or numbness in the distribution of the affected nerve, although many patients remain asymptomatic. The presence of perineural invasion is associated with higher local recurrence rates and may influence the decision to add adjuvant radiotherapy after surgical excision.

Diagnosis

Biopsy Techniques

Because the lesion can be deep and fibrotic, a superficial shave biopsy may miss the diagnostic desmoplastic component. An incisional or punch biopsy that reaches the deep dermis and subcutis is preferred to obtain adequate tissue for histology and immunohistochemistry. In some centers, a narrow excisional biopsy with a 1‑2 mm margin is performed when the clinical suspicion is high, providing both diagnosis and preliminary treatment.

Immunohistochemistry

Immunohistochemistry (IHC) uses antibodies that bind to specific proteins in tissue sections, allowing pathologists to confirm melanocytic lineage and distinguish desmoplastic melanoma from mimics. The most commonly used markers include S100 protein, SOX10, and melan‑A (MART‑1). S100 and SOX10 are highly sensitive and highlight the spindled melanocytes within the dense stroma, whereas melan‑A and HMB‑45 are often negative in the desmoplastic areas but may be positive in any conventional component. A panel approach increases diagnostic confidence.

Molecular Pathology

Next‑generation sequencing studies have shown that desmoplastic melanoma harbors a high mutational burden driven by ultraviolet‑signature mutations, frequently involving NF1, TP53, and BRAF (non‑V600E). The NF1 loss is more common than in other subtypes and may explain the prominent neural differentiation. While targeted therapies against BRAF V600E are rarely applicable, emerging data suggest that immune checkpoint inhibitors can be effective in advanced disease, likely due to the high neoantigen load.

Staging and Treatment

Surgical Management

Wide local excision remains the cornerstone of treatment. Current guidelines recommend margins of 1 cm for tumors up to 1 mm in Breslow thickness, 1‑2 cm for thicknesses between 1 mm and 2 mm, and 2 cm for tumors thicker than 2 mm. Because desmoplastic melanoma often extends beyond clinically apparent borders, some surgeons advocate for slightly wider margins or intraoperative margin assessment using frozen sections. Achieving clear peripheral and deep margins is the most important predictor of local control.

Role of Radiotherapy

Adjuvant radiotherapy is considered for patients with positive or close margins, extensive perineural invasion, or recurrent disease. Radiation fields typically encompass the primary tumor bed and, when indicated, the regional nerve pathways. Studies report improved local control rates when radiotherapy is added in high‑risk scenarios, although overall survival benefit remains uncertain. The decision is individualized and discussed in a multidisciplinary tumor board.

Sentinel Lymph Node Biopsy

Sentinel lymph node biopsy (SLNB) identifies the first draining lymph node(s) to assess microscopic nodal spread. In pure desmoplastic melanoma, the sentinel node positivity rate is low, estimated around 5 % or less, leading some guidelines to consider SLNB optional for pure tumors without high‑risk features. In mixed desmoplastic melanoma, the positivity rate approaches that of conventional melanoma (15‑25 %), and SLNB is generally recommended for tumors ≥1 mm thick or with ulceration. The procedure carries minimal morbidity and provides prognostic information.

Systemic Therapy for Advanced Disease

For unresectable or metastatic desmoplastic melanoma, immune checkpoint inhibitors (anti‑PD‑1 agents such as pembrolizumab or nivolumab) have demonstrated response rates comparable to other melanoma subtypes, despite the low tumor mutational burden in some series. BRAF/MEK inhibitors are rarely used because activating BRAF V600 mutations are uncommon. Clinical trials exploring combination immunotherapy, intralesional therapy, and adjuvant checkpoint inhibition are ongoing and may refine future standards.

Prognosis and Outlook

Overall survival for desmoplastic melanoma is generally favorable compared with other melanoma subtypes of similar thickness, largely because distant metastasis is less common. Five‑year disease‑specific survival for localized pure desmoplastic melanoma exceeds 90 % in most series. The main challenge is local recurrence, which can occur in 15‑30 % of cases, especially when margins are inadequate or perineural invasion is present. Mixed desmoplastic melanoma carries a prognosis more aligned with conventional melanoma, with nodal status being the dominant prognostic factor.

Comparison with Other Melanoma Subtypes

Follow‑Up and Surveillance

After definitive treatment, patients enter a structured surveillance program. The National Comprehensive Cancer Network recommends a complete skin examination every 3 to 6 months for the first two years, then every 6 to 12 months for the next three years, and annually thereafter. Imaging with ultrasound of the regional nodal basin or cross‑sectional imaging (CT, MRI, PET‑CT) is reserved for patients with high‑risk features such as thick tumors, positive sentinel nodes, or clinical suspicion of recurrence. Patients should be educated on self‑examination and prompt reporting of new or changing lesions, especially in the previously treated field.

• Clinical skin exam: every 3‑6 months (years 1‑2), then 6‑12 months (years 3‑5)
• Regional nodal ultrasound: consider for high‑risk primary or after positive SLNB
• Cross‑sectional imaging: baseline for stage III/IV, then as clinically indicated
• Patient self‑exam: monthly, with emphasis on scar site and draining nodal basins
• Multidisciplinary review: at each follow‑up for complex cases

Quality of Life Considerations

Because desmoplastic melanoma frequently involves the face and neck, surgical resection and possible radiotherapy can affect cosmetic appearance, speech, swallowing, and sensory function. Early involvement of reconstructive surgeons, speech therapists, and psychosocial support services mitigates functional deficits. Patient‑reported outcome measures indicate that most individuals regain satisfactory quality of life within 12 months, although long‑term neuropathy from perineural invasion may persist.

References

1. National Cancer Institute. Desmoplastic Melanoma Treatment (PDQ®) – Health Professional Version. Available at: https://www.cancer.gov/types/skin/hp/melanoma-treatment-pdq Accessed: 27 August 2026.
2. American Cancer Society. Melanoma Skin Cancer – Desmoplastic Melanoma. Available at: https://www.cancer.org/cancer/melanoma-skin-cancer/about/what-is-melanoma.html Accessed: 27 August 2026.
3. American Academy of Dermatology. Desmoplastic Melanoma: Diagnosis and Management. Available at: https://www.aad.org/public/diseases/skin-cancer/melanoma/desmoplastic Accessed: 27 August 2026.
4. World Health Organization / International Agency for Research on Cancer. WHO Classification of Skin Tumours, 5th ed. Lyon: IARC; 2023.
5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Melanoma: Cutaneous. Version 2.2024. Available at: https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf Accessed: 27 August 2026.
6. Coit DG, Thompson JA, et al. Melanoma, Version 2.2024, NCCN Guidelines. Journal of the National Comprehensive Cancer Network. 2024;22(4):e2401.
7. Busam KJ, et al. Desmoplastic melanoma: a clinicopathologic analysis of 115 cases. American Journal of Surgical Pathology. 2004;28(5):607‑614.
8. Murali R, et al. Neurotropism in desmoplastic melanoma: incidence and prognostic significance. Modern Pathology. 2010;23(9):1245‑1252.
9. Spillane AJ, et al. Sentinel node biopsy in desmoplastic melanoma: a systematic review and meta‑analysis. Journal of Clinical Oncology. 2015;33(12):1385‑1392.
10. Quaglino P, et al. Radiotherapy for desmoplastic melanoma: a retrospective multicenter study. Radiotherapy and Oncology. 2018;128(2):210‑216.
11. Guitart J, et al. Immunohistochemical profile of desmoplastic melanoma: utility of SOX10 and p75NTR. Journal of Cutaneous Pathology. 2012;39(10):945‑952.
12. Elder DE, et al. Lever’s Histopathology of the Skin, 12th ed. Philadelphia: Wolters Kluwer; 2022.